PRKAA2 and polycystic ovary syndrome: Pharmacological modulation of this axis, using natural compounds and GLP-1 receptor agonists, has shown promise in treating metabolic syndrome [25], prompting interest in targeting SIRT1/AMPK signaling to manage multiple aspects of PCOS.